Vous êtes ici

BioHarvest Sciences Inc.

BioHarvest Sciences Inc.
Liste d'échange: 
CSE
Statut: 
Active
Industrie: 
Life Sciences
Symbole: 
BHSC
Indice CSE: 
Devise: 

BioHarvest Sciences Inc. (CSE: BHSC) is a leader in Botanical Synthesis, leveraging its patented technology process to grow plant-based molecules without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and production organization (CDMO) on behalf of customers seeking complex molecules, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit www.bioharvest.com.

Vous êtes ici

BioHarvest Sciences Inc. (BHSC)

SEDAR Information

Information d'entreprise

Addresse
1140, 625 Howe St.
Vancouver, BC V6C 2T6
Canada
Téléphone
604-662-1186
Fax
604-685-9182
Courriel
[email protected]
URL
http://www.cannavcell.com
Date d’inscription à la cote
Mardi, août 4, 2015
Agent de transfert
National Securities Administrators Ltd.

Capitalisation

Capitalisation: 
16425077
Réservé à l'émission: 
3700736

Company Officers

Ilan Sobel, CEO
Alan Rootenberg, CFO
Yochi Hagay, CTO
Ilana Belzer, COO
Brian Cornblatt, Chief Medical Officer
Zaki Rakib, President, Chairman & Director
David Ryan , Vice President of Investor Relations, Secretary & Director
Bar Moreh, Vice-President, Finance
Malkit Azachi, Vice-President, Research & Development
Michael Sapir, Vice-President, Regulatory Affairs
Jared Turner , Vice-President, D2C Products Business Unit
Matthew Zrebiec, Vice-President, Business Development
Vivien Rakib, Director
Jake Fiddick, Director
David Tsur, Director
Anna Tenstam, Vice-President, Business Development, Cosmeceuticals and Injectables

Bulletins

30/05/2024

2024-0529 – Consolidation - BioHarvest Sciences Inc. (BHSC)

Le 30 mai/May 2024

BioHarvest Sciences Inc. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every thirty five (35) pre-consolidated common shares.

As a result, the outstanding shares of the company will be reduced to approximately 16,425,077 common shares.

The name and symbol will not change.